MENU

ETNB Stock Tickeron detected bearish Stock Pattern: Dead Cat Bounce ETNB on December 12, 2024, netting in a 20.13% gain over 1 month

A.I.dvisor
at Tickeron.com
Loading...
+20.13% Gain from a Successful pattern Dead Cat Bounce
ETNB - 89bio
Tickeron
Ticker: ETNB
Company: 89bio
Gain from shortening: +20.13%
Confirmed: 12/12/24
Succeeded: 01/15/25
Total length: 34 days
On December 12, 2024, A.I.dvisor detected a Dead Cat Bounce Pattern (Bearish) for 89bio (ETNB, $7.85). On December 12, 2024, A.I.dvisor confirmed the Bearish pattern, setting a target price of the stock. On January 15, 2025, the stock hit the target price of $6.16 – resulting in a +2 gain for traders who shorted the stock on the pattern detection date.

ETNB's Indicator enters downward trend

The Aroon Indicator for ETNB entered a downward trend on January 14, 2025. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 223 similar instances where the Aroon Indicator formed such a pattern. In of the 223 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on January 07, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on ETNB as a result. In of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for ETNB turned negative on January 08, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ETNB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ETNB advanced for three days, in of 266 cases, the price rose further within the following month. The odds of a continued upward trend are .

ETNB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.962) is normal, around the industry mean (15.339). P/E Ratio (0.000) is within average values for comparable stocks, (87.552). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.851). ETNB has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (0.000) is also within normal values, averaging (263.778).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ETNB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ETNB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
ETNB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of innovative therapies for nonalcoholic steatohepatitis (NASH), liver and cardio-metabolic diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
142 Sansome Street
Phone
+1 415 432-9270
Employees
70
Web
https://www.89bio.com